Clinical Trials Directory

Trials / Terminated

TerminatedNCT02757391

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Pilot Study of Feasibility and Safety of Personalized Autologous CD8+ T Cell Therapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
1 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body. Tumor cells and blood are used to help create an adoptive T cell therapy, such as CD8+ T cell therapy, that is individually designed for a patient and may help doctors learn more about genetic changes in the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CD8+ T cell therapy and pembrolizumab may work better in treating patients with gastrointestinal tumors.

Detailed description

PRIMARY OBJECTIVES: I. Assess the safety of using a personalized adoptive T cell therapy in patients with advanced gastrointestinal malignancies. SECONDARY OBJECTIVES: I. Assess the persistence of an immune response after T cell infusion. II. Determine the clinical benefit of adoptive T cell therapy in advanced gastrointestinal cancers. OUTLINE: Beginning 2 days prior to CD8+ T cell infusion, patients receive cyclophosphamide intravenously (IV) over 30 minutes. Patients undergo CD8+ T cell infusion IV over 2 hours on day 0 and receive aldesleukin subcutaneously (SC) twice daily (BID) on days 1-14. Beginning on day 1 about 24 hours after CD8+ T cell infusion, patients receive pembrolizumab IV over 30-60 minutes on weeks 3, 6, 12, and 15. After completion of study treatment, patients are followed up for 24 weeks.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAdoptive ImmunotherapyUndergo CD8 +T cell therapy
BIOLOGICALAldesleukinGiven SC
DRUGCyclophosphamideGiven IV
OTHERLaboratory Biomarker AnalysisCorrelative studies
BIOLOGICALPembrolizumabGiven IV

Timeline

Start date
2019-08-09
Primary completion
2020-10-02
Completion
2020-10-02
First posted
2016-05-02
Last updated
2020-10-30

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT02757391. Inclusion in this directory is not an endorsement.